Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21373140 | 0.87 | RAPGEF4 (0.42) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4441787 | 0.87 | CYP2C9 (0.41) | POLBMAPTMEN1KMT2AGAA | |
| SCHEMBL15866395 | 0.82 | CA1 (0.36) | F2PRSS1PRSS2PRSS3HIF1A | |
| SCHEMBL3030889 | 0.78 | HIF1A (0.37) | POLBMAPTTP53MAPK1NPSR1 | |
| SCHEMBL19190535 | 0.77 | CA1 (0.33) | HIF1ACA1CA2CA9CA12 | |
| SCHEMBL21386603 | 0.75 | USP30 (0.31) | HIF1ACA1CA2CA9CA12 | |
| SCHEMBL14081665 | 0.74 | CYP1A2 (0.39) | F2PRSS1PRSS2PRSS3POLB | |
| SCHEMBL16207740 | 0.74 | CA1 (0.37) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL20561771 | 0.71 | HIF1A (0.37) | F2PRSS1PRSS2PRSS3HIF1A | |
| SCHEMBL878145 | 0.71 | F11 (0.34) | F2PRSS1PRSS2PRSS3HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-RE49500-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-25 | — | — | US | disclosed |
| EP-3943489-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3608315-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2021-08-11 | — | — | EP | disclosed |
| US-RE48266-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3608315-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3305776-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47318-E1 | Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3305776-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2018-04-11 | — | — | EP | disclosed |
| US-7345054-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-18 | — | — | US | disclosed |
| US-7304061-B2 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1753738-A1 | PYRROLE COMPOUNDS AS INIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1730134-A1 | PYRIDINE INHIBITORS OF ERK2 AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-05-18 | — | — | US | disclosed |
| US-20060019953-A1 | Pyridine inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2006-01-26 | — | — | US | disclosed |
| WO-2005113541-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005100342-A1 | PYRIDINE INHIBITORS OF ERK2 AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2005-10-20 | — | — | US | disclosed |
| US-20040029857-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234059-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, MAPK3, CDK1 | RAPGEF4 2423/4885F2 2541/4885PRSS1 1832/4885 |
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | MAPK1, MAP3K1, MAP3K20 | RAPGEF4 704/4885F2 3590/4885PRSS1 2082/4885 |
| US-20040029857-A1 | Heterocyclic inhibitors of ERK2 and uses thereof | CDK2, CDK1, CDK3 | RAPGEF4 3051/4885F2 3020/4885PRSS1 2447/4885 |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | MAP3K1, MAP4K2, MAP3K4 | RAPGEF4 731/4885F2 4769/4885PRSS1 2251/4885 |
| US-20060019953-A1 | Pyridine inhibitors of ERK2 and uses thereof | MAP4K2, MAP3K20, MAP3K1 | RAPGEF4 354/4885F2 3709/4885PRSS1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.